How To Improve Energy Efficiency At Home Easy

Are you spending so much money on energy in your home and want to save more energy? Well you can! The first thing you need to do is do an energy assessment to know where you can potentially save big on energy. You will then be able to make the…

Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio

This Announcement Contains Inside Information Within The Meaning Of The EU Market Abuse Regulation No.596/2014 Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio[1] to 15 companies Arix commits $11 million (£8.4 million)[2] for 11.2% ownership stake Co-investment with strategic partner Takeda and…

Wellthy Therapeutics Presents Real-world Evidence to Show Digital Therapeutics can Both Improve Patient Outcomes and aid HCPs in Decision Making

Results shared at the American Diabetes Association”s (ADA) 78th Scientific Sessions Wellthy Therapeutics , a leading digital health company in chronic disease management through its digital therapeutics platform Wellthy Care, recently announced results from its real-world studies, showing significant improvements in patient outcomes along with enhanced decision support for all…

PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe

PharmaMar will receive an up-front payment of 2 million euros This agreement will replace the current agreement between PharmaMar and Swedish Orphan Biovitrum International PharmaMar (MCE: PHM) has announced today the signing of an agreement with Impilo Pharma, a part of Immedica Group, for the exclusive promotion and distribution of its antitumour compound, Yondelis®, throughout the Nordic countries and Eastern…

4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours

4D pharma plc (AIM: DDDD) today announced an agreement with a subsidiary of MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) to conduct a clinical trial evaluating the combination of KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by MSD, and 4D pharma”s live biotherapeutic candidate MRx0518 in patients with…

EP Solutions’ Scientific and Mathematics Advisory Boards Endorse Company Strategy

Dr. Joaquin Azpilicueta, M.D., EP Solutions CEO reports the outcome of the meetings with the Scientific Advisory Board and the Mathematics Advisory Board celebrated in February and March 2018 respectively.      (Logo: ) The Scientific Advisory Board, with members that hold prominent positions in the cardiac electrophysiology community like Prof.…

Utilizzando il sito, accetti l'utilizzo dei cookie da parte nostra. maggiori informazioni

Questo sito utilizza i cookie per fornire la migliore esperienza di navigazione possibile. Continuando a utilizzare questo sito senza modificare le impostazioni dei cookie o cliccando su "Accetta" permetti il loro utilizzo.

Chiudi